Eli Lilly made good on its threat to withhold 340B drug discounts from hospitals that refused to submit claims data. Hospital groups are calling the policy unlawful, arguing that the company has no legal authority to create its own compliance requirements for a federal program.
Employers are advocating for changes to the 340B Drug Pricing Program, arguing that it allows hospitals to "buy low and sell high" by purchasing discounted medications and charging insured patients full price.
Discover the top AI-powered EAP providers for 2026. Compare platforms like Kyan Health and Spring Health on triage speed, global reach, and clinical quality to transform workforce wellbeing.
Johnson & Johnson announced last week a major change in the way it offers 340B pricing for two medications. The change is "inconsistent" with the 340B statute, according to HRSA.